{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-031161","form_type":"8-K","ticker":"LUCD","cik":"0001799011","company_name":"Lucid Diagnostics Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.556169+00:00","generated_at":"2026-05-31T10:06:26.319184+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lucid Diagnostics Q2 2024: EsoGuard test volume +31% QoQ to record 3,147; revenue $1.0M","bullets":["EsoGuard volume 3,147 (record), up 31% sequentially and 44% YoY; revenue $1.0M flat QoQ but +514% YoY.","GAAP net loss $11.0M ($0.23/share); non-GAAP adjusted loss $9.7M ($0.20/share).","Positive clinical data: ENVET-BE study shows 2.4x increased yield; BE-1 study 88% sensitivity, 99% NPV.","Cash $24.9M after $11.6M Series B-1 preferred stock issuance; held CMS MAC Palmetto GBA MolDX meeting.","First major #CheckYourFoodTube event with upfront contracted payment; revenue cycle management improving."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-031161","json":"https://secwatch.observer/filing/0001493152-24-031161.json","markdown":"https://secwatch.observer/filing/0001493152-24-031161.md","text":"https://secwatch.observer/filing/0001493152-24-031161.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799011/000149315224031161/0001493152-24-031161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799011/000149315224031161/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:06:26.319184+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}